Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 4:07 pm Purchase | 2022-12-31 | 13G | Milestone Pharmaceuticals Inc. MIST | Venrock Healthcare Capital Partners III, L.P. | 2,208,812 6.400% | 136,803 (+6.60%) | Filing History |
| 2023-02-14 4:06 pm Purchase | 2022-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN | Venrock Healthcare Capital Partners III, L.P. | 3,707,891 7.700% | 641,650 (+20.93%) | Filing History |
| 2023-01-09 4:06 pm Purchase | 2022-12-28 | 13G | KalVista Pharmaceuticals, Inc. KALV | Venrock Healthcare Capital Partners III, L.P. | 2,916,667 8.600% | 2,916,667 (New Position) | Filing History |
| 2022-12-23 4:15 pm Purchase | 2022-12-13 | 13G | Cabaletta Bio, Inc. CABA | Venrock Healthcare Capital Partners III, L.P. | 1,895,285 6.500% | 1,895,285 (New Position) | Filing History |
| 2022-09-19 9:14 pm Purchase | 2022-09-09 | 13G | Milestone Pharmaceuticals Inc. MIST | Venrock Healthcare Capital Partners III, L.P. | 2,072,009 6.900% | 2,072,009 (New Position) | Filing History |
| 2022-08-26 7:24 pm Purchase | 2022-08-16 | 13G | Terns Pharmaceuticals, Inc. TERN | Venrock Healthcare Capital Partners III, L.P. | 3,066,241 8.200% | 3,066,241 (New Position) | Filing History |
| 2022-02-14 4:19 pm Purchase | 2021-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Venrock Healthcare Capital Partners III, L.P. | 2,205,268 9.990% | 262,213 (+13.49%) | Filing History |
| 2021-10-14 4:05 pm Purchase | 2021-10-04 | 13G | Viridian Therapeutics, Inc. VRDN | Venrock Healthcare Capital Partners III, L.P. | 1,943,055 9.990% | 1,943,055 (New Position) | Filing History |
| 2021-02-16 4:11 pm Purchase | 2020-12-31 | 13G | Trillium Therapeutics Inc. TRIL | Venrock Healthcare Capital Partners III, L.P. | 4,040,000 4.000% | 1,250,000 (+44.80%) | Filing History |
| 2021-02-16 4:08 pm Sale | 2020-12-31 | 13G | Galera Therapeutics, Inc. GRTX | Venrock Healthcare Capital Partners III, L.P. | 917,860 3.700% | -825,528 (-47.35%) | Filing History |
| 2020-11-04 4:54 pm Purchase | 2020-10-08 | 13G | Cardiff Oncology, Inc. CRDF | Venrock Healthcare Capital Partners III, L.P. | 1,714,286 5.700% | 1,714,286 (New Position) | Filing History |
| 2020-11-04 4:52 pm Purchase | 2020-10-16 | 13G | Galera Therapeutics, Inc. GRTX | Venrock Healthcare Capital Partners III, L.P. | 1,743,388 7.000% | 1,743,388 (New Position) | Filing History |